
Commentary|Podcasts|November 18, 2025
Inside AHA’s Late-Breaking Lipid Trials: The Rise of Oral PCSK9 Inhibition
Advertisement
This week, host Craig Beavers spoke with Joe Sassine, PharmD, BCPS, BCACP, CLS, about several key trials presented at the American Heart Association 2025 Scientific Sessions.
Show notes:
- VESALIUS-CV trial:
https://www.nejm.org/doi/full/10.1056/NEJMoa2514428 CORAL REEF trial
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Semaglutide Shows Direct Organ-Protective Benefits Beyond Weight Loss in HFpEF
2
Immune Synergy May Explain Why Some Patients Achieve Durable Remission With Cilta-Cel
3
Neladalkib Shows Durable Responses in Heavily Pretreated ALK-Positive Lung Cancer
4
November 2025 Pharmacy Policy Updates
5















































































































































































































